Gilead Sciences, Inc. $GILD Stock Bought by Leuthold Group LLC

Leuthold Group LLC lifted its position in shares of Gilead Sciences, Inc. (NASDAQ:GILD) by 9.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 58,247 shares of the biopharmaceutical company’s stock after buying an additional 5,216 shares during the quarter. Leuthold Group LLC’s holdings in Gilead Sciences were worth $8,682,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in GILD. Bank of Nova Scotia purchased a new stake in shares of Gilead Sciences during the second quarter worth about $100,056,000. OMERS ADMINISTRATION Corp purchased a new position in shares of Gilead Sciences in the 2nd quarter valued at approximately $55,754,000. Groupe la Francaise raised its position in shares of Gilead Sciences by 30.9% in the 2nd quarter. Groupe la Francaise now owns 49,627 shares of the biopharmaceutical company’s stock valued at $6,270,000 after purchasing an additional 11,712 shares during the last quarter. Baird Financial Group Inc. boosted its stake in Gilead Sciences by 3.6% in the 2nd quarter. Baird Financial Group Inc. now owns 292,295 shares of the biopharmaceutical company’s stock worth $36,929,000 after purchasing an additional 10,206 shares in the last quarter. Finally, Headlands Technologies LLC acquired a new stake in Gilead Sciences in the 2nd quarter worth approximately $6,251,000. Hedge funds and other institutional investors own 83.67% of the company’s stock.

Gilead Sciences Stock Up 1.5%

Shares of NASDAQ:GILD opened at $169.32 on Tuesday. The company has a market capitalization of $210.01 billion, a price-to-earnings ratio of -53.58 and a beta of 0.35. Gilead Sciences, Inc. has a 12-month low of $116.88 and a 12-month high of $176.58. The business has a 50-day moving average price of $153.51 and a 200 day moving average price of $141.14. The company has a current ratio of 1.38, a quick ratio of 0.95 and a debt-to-equity ratio of 1.84.

Gilead Sciences (NASDAQ:GILD) last posted its earnings results on Thursday, October 29th. The biopharmaceutical company reported $2.55 earnings per share for the quarter, beating the consensus estimate of $2.19 by $0.36. The firm had revenue of $8.30 billion during the quarter, compared to the consensus estimate of $7.81 billion. Gilead Sciences had a negative net margin of 12.47% and a negative return on equity of 1.85%. The firm’s revenue for the quarter was up 6.8% on a year-over-year basis. During the same quarter last year, the firm earned $2.47 EPS. Sell-side analysts expect that Gilead Sciences, Inc. will post -1.07 EPS for the current year.

Gilead Sciences Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, December 30th. Investors of record on Tuesday, December 15th will be paid a dividend of $0.82 per share. This represents a $3.28 annualized dividend and a yield of 1.9%. The ex-dividend date of this dividend is Tuesday, December 15th. Gilead Sciences’s dividend payout ratio is presently -103.80%.

Insider Buying and Selling at Gilead Sciences

In other Gilead Sciences news, CFO Andrew Dickinson sold 3,000 shares of the stock in a transaction that occurred on Thursday, October 15th. The shares were sold at an average price of $156.22, for a total transaction of $468,660.00. Following the sale, the chief financial officer directly owned 161,096 shares in the company, valued at $25,166,417.12. This represents a 1.83% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Wettan Keeley M. Cain sold 3,399 shares of the firm’s stock in a transaction that occurred on Friday, November 6th. The shares were sold at an average price of $164.11, for a total transaction of $557,809.89. Following the completion of the transaction, the executive vice president directly owned 5,360 shares of the company’s stock, valued at $879,629.60. This represents a 38.81% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold 242,709 shares of company stock valued at $39,503,427 in the last quarter. Corporate insiders own 0.30% of the company’s stock.

Analyst Ratings Changes

A number of equities research analysts recently commented on the company. BMO Capital Markets reiterated an “outperform” rating and issued a $184.00 target price on shares of Gilead Sciences in a research report on Friday, October 30th. JPMorgan Chase & Co. lifted their target price on shares of Gilead Sciences from $170.00 to $190.00 and gave the company an “overweight” rating in a report on Friday, October 30th. Jefferies Financial Group set a $196.00 price target on Gilead Sciences in a report on Wednesday, November 4th. Morgan Stanley upped their target price on Gilead Sciences from $163.00 to $183.00 and gave the stock an “overweight” rating in a research note on Friday, October 30th. Finally, UBS Group increased their target price on Gilead Sciences from $175.00 to $195.00 and gave the company a “buy” rating in a research report on Friday, October 30th. Twenty-three equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $170.15.

Gilead Sciences Profile

Gilead Sciences, Inc is a biopharmaceutical company that discovers, develops and commercializes medicines for serious diseases. Founded in 1987 and headquartered in Foster City, California, the company focuses on antiviral therapies, including treatments and preventive medicines for HIV and medicines for viral hepatitis. Its products include Biktarvy for HIV and Epclusa for hepatitis C.

Gilead also develops medicines in areas such as oncology and inflammatory diseases. Its portfolio includes Veklury (remdesivir), an antiviral medicine used to treat COVID-19.